As of 7 Jul 2026, Balaxi Pharma share price is ₹24.25. The stock opened at ₹24.00, compared to its previous close of ₹24.00. During today's trading session, Balaxi Pharma share price moved in the range of ₹23.62 to ₹24.80, with an average price of ₹24.21 for the day. Looking at its last 52-week, the stock has touched a low of ₹15.20 and a high of ₹54.70. On the performance front, Balaxi Pharma share price has declined by 14.82% over the last six months and is down 51.30% on a year-on-year basis.
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,59,005.00 | 39.88 | 5.49 | 13.74% | 0.61 | 17.33% | 93.24 | 0.84% | 0.56 | 10.90 |
| Divis Laboratories | 1,81,867.00 | 70.82 | 10.85 | 15.32% | 0.00 | 19.56% | 629.49 | 0.44% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,63,246.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,18,854.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Zydus Lifesciences | 1,14,518.00 | 22.35 | 4.22 | 18.59% | 0.31 | 17.35% | 237.30 | 0.09% | 0.39 | 35.38 |
| Dr. Reddy's Laboratories | 1,14,246.00 | 24.97 | 2.75 | 11.64% | 0.15 | 13.65% | 3.32 | 0.64% | 0.63 | 38.68 |
| Lupin | 1,13,963.00 | 21.28 | 5.08 | 23.76% | 0.04 | 24.88% | 659.05 | 0.72% | 0.61 | 129.18 |
| Mankind Pharma | 1,04,911.00 | 54.13 | 6.44 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 92,574.00 | 26.43 | 2.44 | 9.25% | 0.19 | 11.76% | 391.14 | 0.25% | 0.48 | 41.58 |
| Laurus Labs | 82,615.00 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹292.56 | ₹241.29 | ₹336.43 | ₹279.39 |
| Other Income | ₹2.36 | ₹0.63 | ₹2.64 | ₹4.97 |
| Total Revenue | ₹294.92 | ₹241.93 | ₹339.07 | ₹284.36 |
| Total Expenses | ₹266.25 | ₹201.62 | ₹282.15 | ₹229.84 |
| Profit Before Tax | ₹28.67 | ₹2.02 | ₹56.92 | ₹54.52 |
| Tax | ₹3.60 | ₹4.40 | ₹10.96 | ₹6.86 |
| Profit After Tax | ₹25.07 | -₹2.39 | ₹45.96 | ₹47.66 |
| EPS - Basic | ₹4.54 | -₹0.46 | ₹45.81 | ₹47.66 |
| EPS - Diluted | ₹4.54 | -₹0.46 | ₹45.40 | ₹47.66 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹28.67 | ₹2.02 | ₹56.92 | ₹54.52 |
| Income before WC changes | ₹36.10 | ₹0.87 | ₹64.96 | ₹55.70 |
| Change in Assets | -₹55.02 | ₹14.35 | -₹31.74 | -₹43.32 |
| Change in Liabilities | -₹12.87 | -₹3.67 | -₹15.05 | ₹27.36 |
| Change in WC | -₹67.89 | ₹10.68 | -₹46.79 | -₹15.97 |
| Cash flow from Operations | -₹35.00 | ₹4.87 | ₹6.08 | ₹34.14 |
| Cash flow from Investing | -₹21.76 | -₹1.05 | -₹10.57 | -₹28.45 |
| Cash flow from Financing | ₹33.88 | ₹30.25 | ₹25.51 | -₹0.16 |
| Total Cash Flow | -₹22.89 | ₹34.07 | ₹21.02 | ₹5.53 |
| Cash (Start of the year) | ₹62.29 | ₹28.21 | ₹7.19 | ₹1.66 |
| Cash (End of the year) | ₹39.40 | ₹62.29 | ₹28.21 | ₹7.19 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹67.58 | ₹48.17 | ₹46.16 | ₹35.47 |
| Current Assets | ₹242.77 | ₹210.17 | ₹193.51 | ₹141.00 |
| Total Assets | ₹310.34 | ₹258.34 | ₹239.67 | ₹176.47 |
| Current Liabilities | ₹54.53 | ₹54.20 | ₹53.13 | ₹63.27 |
| Net Current Asset | ₹188.23 | ₹155.97 | ₹140.38 | ₹77.74 |
| Non-Current Liabilities | ₹24.07 | ₹2.78 | ₹3.66 | ₹0.04 |
| Equity Capital | ₹231.74 | ₹201.36 | ₹182.88 | ₹113.16 |
| Total Equity & Liabilities | ₹310.34 | ₹258.34 | ₹239.67 | ₹176.47 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹60.99 | ₹70.20 | ₹108.14 | ₹101.29 |
| Other Income | ₹5.37 | ₹2.40 | ₹6.60 | ₹2.75 |
| Total Revenue | ₹66.36 | ₹72.59 | ₹114.74 | ₹104.04 |
| Total Expenses | ₹61.07 | ₹67.01 | ₹92.29 | ₹84.34 |
| Profit Before Tax | ₹5.29 | ₹5.58 | ₹22.45 | ₹19.70 |
| Tax | ₹1.69 | ₹1.93 | ₹6.23 | ₹5.03 |
| Profit After Tax | ₹3.60 | ₹3.65 | ₹16.22 | ₹14.67 |
| EPS - Basic | ₹0.65 | ₹0.71 | ₹16.17 | ₹14.67 |
| EPS - Diluted | ₹0.65 | ₹0.71 | ₹16.02 | ₹14.67 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹5.29 | ₹5.58 | ₹22.45 | ₹19.70 |
| Income before WC changes | ₹7.80 | ₹7.63 | ₹23.43 | ₹20.01 |
| Change in Assets | -₹10.93 | ₹0.57 | -₹27.37 | -₹6.00 |
| Change in Liabilities | -₹2.84 | -₹4.96 | ₹2.29 | ₹0.56 |
| Change in WC | -₹13.77 | -₹4.39 | -₹25.08 | -₹5.44 |
| Cash flow from Operations | -₹7.60 | -₹1.83 | -₹7.07 | ₹8.89 |
| Cash flow from Investing | -₹24.98 | ₹0.46 | -₹2.29 | -₹6.87 |
| Cash flow from Financing | ₹17.21 | ₹27.55 | ₹26.39 | -₹1.64 |
| Total Cash Flow | -₹15.37 | ₹26.19 | ₹17.03 | ₹0.38 |
| Cash (Start of the year) | ₹44.06 | ₹17.87 | ₹0.84 | ₹0.47 |
| Cash (End of the year) | ₹28.68 | ₹44.06 | ₹17.88 | ₹0.84 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹54.84 | ₹31.46 | ₹30.70 | ₹27.84 |
| Current Assets | ₹119.60 | ₹122.90 | ₹99.02 | ₹54.08 |
| Total Assets | ₹174.45 | ₹154.36 | ₹129.72 | ₹81.92 |
| Current Liabilities | ₹43.76 | ₹30.04 | ₹34.83 | ₹23.97 |
| Net Current Asset | ₹75.84 | ₹92.86 | ₹64.19 | ₹30.11 |
| Non-Current Liabilities | ₹2.83 | ₹2.78 | ₹2.79 | ₹0.04 |
| Equity Capital | ₹127.85 | ₹121.55 | ₹92.11 | ₹57.91 |
| Total Equity & Liabilities | ₹174.45 | ₹154.36 | ₹129.72 | ₹81.92 |
Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across the Americas, Africa and the Caribbean islands. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It is engaged in International Wholesale Distribution of Pharmaceuticals. The Company’s products include Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents, and Laxative. Its Boadent brand includes anticavity dental toothpaste. Its subsidiaries are Balaxi Global DMCC, Dubai and Balaxi healthcare Ecuador.
Balaxi Pharma share price is ₹24.25 as on 07 Jul, 2026, 15:27 IST.
In the last 1 year, Balaxi Pharma delivered a return of -51.30%. The Balaxi Pharma share price hit a high of ₹54.70 and low of ₹15.20.
The Mutual Fund Shareholding in Balaxi Pharma was 0.00% at the end of Mar 2026.
The 52-week high and low of Balaxi Pharma share is ₹54.70 and ₹15.20 as of 07 Jul, 2026.
The market capitalisation of Balaxi Pharma is ₹132.50 Crores as on 07 Jul, 2026.
The stock symbol of Balaxi Pharma is BALAXI on the NSE, , and the ISIN is INE618N01022.
Balaxi Pharma shares closed yesterday at ₹24.00 on NSE
To buy Balaxi Pharma shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
No, shares of Balaxi Pharma or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Balaxi Pharma shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
The PE and PB ratio of Balaxi Pharma is 92.31 and 0.53 respectively, as on 07 Jul, 2026, 15:27 IST.